Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
125,5 USD | +0,81% | -3,05% | +15,15% |
31/05 | Trodelvy di Gilead fallisce nello studio sul cancro alla vescica, allunga modestamente la sopravvivenza del cancro al polmone | RE |
31/05 | Aggiornamento settoriale: Assistenza sanitaria | MT |
Attività
- vendita di prodotti farmaceutici (69,7%): per il trattamento di ipertensione, osteoporosi, aterosclerosi, malattie respiratorie, batteriche e fungine, oftalmologiche e urologiche, emicrania acuta, perdita di capelli negli uomini, ecc;
- vendita di vaccini (18%);
- vendita di prodotti per la salute degli animali (9,4%);
- altro (2,9%).
Le vendite nette sono distribuite geograficamente come segue: Stati Uniti (45,9%), Europa/Medio Oriente/Africa (24,5%), Cina (8,8%), Giappone (6,1%), Asia/Pacifico (6,1%), America Latina (4,3%) e altro (4,3%).
Numero di dipendenti: 71 000
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Pharmaceutical
89,1
%
| 52 005 | 87,7 % | 53 583 | 89,1 % | +3,03% |
Animal Health
9,4
%
| 5 550 | 9,4 % | 5 625 | 9,4 % | +1,35% |
Other
1,5
%
| 1 728 | 2,9 % | 907 | 1,5 % | -47,51% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
47,4
%
| 27 206 | 45,9 % | 28 480 | 47,4 % | +4,68% |
Europe, Middle East and Africa
22,0
%
| 14 493 | 24,4 % | 13 254 | 22,0 % | -8,55% |
China
11,3
%
| 5 191 | 8,8 % | 6 802 | 11,3 % | +31,03% |
Asia Pacific
5,4
%
| 3 614 | 6,1 % | 3 225 | 5,4 % | -10,76% |
Japan
5,3
%
| 3 629 | 6,1 % | 3 164 | 5,3 % | -12,81% |
Latin America
5,1
%
| 2 582 | 4,4 % | 3 086 | 5,1 % | +19,52% |
Other
3,5
%
| 2 568 | 4,3 % | 2 104 | 3,5 % | -18,07% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 01/04/14 |
Director of Finance/CFO | 55 | 01/01/90 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 01/08/20 |
Joseph Romanelli
IRC | Investor Relations Contact | 50 | 01/01/96 |
Peter Dannenbaum
IRC | Investor Relations Contact | - | 01/07/17 |
Andre Musto
PRN | Corporate Officer/Principal | - | 01/07/14 |
Brooke Hinkson
PRN | Corporate Officer/Principal | - | 01/08/15 |
Carol Bowden
PRN | Corporate Officer/Principal | - | 01/04/14 |
Dalton Smart
AUD | Comptroller/Controller/Auditor | 58 | 01/11/09 |
James Matteucci
PRN | Corporate Officer/Principal | - | 01/01/03 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 27/11/07 |
Pamela Craig
BRD | Director/Board Member | 67 | 01/09/15 |
Inge Thulin
BRD | Director/Board Member | 69 | 01/03/18 |
Patricia Russo
BRD | Director/Board Member | 71 | 01/09/95 |
Director/Board Member | 69 | 26/05/20 | |
Robert Davis
CEO | Chief Executive Officer | 57 | 01/04/14 |
Douglas Baker
BRD | Director/Board Member | 65 | 24/05/22 |
Stephen Mayo
BRD | Director/Board Member | 62 | 15/03/21 |
Kathy Warden
BRD | Director/Board Member | 52 | 16/03/20 |
Director/Board Member | 71 | 16/03/20 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 3 577 208 962 | 2 531 418 332 ( 70,77 %) | 1 044 402 655 ( 29,20 %) | 70,77 % |
Partecipazioni
Nome | Azioni | % | Valorizzazione |
---|---|---|---|
13 443 693 | 10.62% | 289 287 301 $ | |
1 739 768 | 5.17% | 21 503 532 $ | |
XILIO THERAPEUTICS, INC. 4.02% | 1 483 414 | 4.02% | 1 498 248 $ |
EVAXION BIOTECH A/S 12.13% | 2 297 884 | 12.13% | 946 728 $ |
Coordinate società
Società del gruppo
Nome | Categoria e settore |
---|---|
MSD Regional Business Support Center GmbH
MSD Regional Business Support Center GmbH Miscellaneous Commercial ServicesCommercial Services Part of Merck & Co., Inc., MSD Regional Business Support Center GmbH is a German company that provides management consulting services. The company is based in Munich, Germany. Jutta König has been the CEO of the company since 2021. |
Miscellaneous Commercial Services
|
Merck Holdings, Inc.
| |
MSD International GmbH (Switzerland)
MSD International GmbH (Switzerland) Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., MSD International GmbH (Switzerland) is a Swiss company that discovers, develops and markets human and animal health products. The company is located in Switzerland. |
Pharmaceuticals: Major
|
Schering Plough International Finance Co. BV
| |
MSD Human Health Holding BV
MSD Human Health Holding BV Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., MSD Human Health Holding BV discovers, develops and markets human and animal health products. The company is based in Oss, Netherlands. |
Pharmaceuticals: Major
|
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme LLC is a pharmaceutical company. The company is based in Kenilworth, NJ. |
Pharmaceuticals: Major
|
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp. Pharmaceuticals: MajorHealth Technology Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ. |
Pharmaceuticals: Major
|
Essex Chemie AG
| |
Merck Sharp & Dohme BV
Merck Sharp & Dohme BV Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme BV is a Dutch company that manufactures and distributes pharmaceutical products. The company is based in Haarlem, the Netherlands. |
Pharmaceuticals: Major
|
Settore
Vendite per attività
Vendite per regione
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
+15,15% | 318 Mrd | |
+40,73% | 739 Mrd | |
+32,83% | 598 Mrd | |
-6,30% | 353 Mrd | |
+4,05% | 285 Mrd | |
+15,00% | 240 Mrd | |
-5,52% | 206 Mrd | |
+6,17% | 164 Mrd | |
-0,45% | 162 Mrd | |
-.--% | 122 Mrd |
- Borsa valori
- Azioni
- Azione MRK
- Società Merck & Co., Inc.